Cases excluded from follow-up included non-serous carcinomas (all MyD88 negative), those with recurrent disease (n = 2), patients who died of post-operative complications or unrelated causes (n = 2) and patients lost to follow-up (further treatment and follow-up at a different institution). This evidence concerns the gene MYD88 and serous adenocarcinoma.